Jenoptik (JEN) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
9 Apr, 2026Executive summary
Implemented a new organizational structure, enhancing accountability, transparency, and customer focus.
Brought new micro-optics fab in Dresden online, supporting future growth and semiconductor inspection capabilities.
Substantial progress on strategic goals, especially in semi inspection and efficiency programs, with intensified cost management.
Management team to be completed with new CEO joining.
Free cash flow significantly improved despite revenue and EBITDA declines.
Financial highlights
Group revenue declined by 6.3% year-over-year to €1,046.0m, with a 1% negative FX impact.
EBITDA reached €192.5m, down 13.1% year-over-year; margin contracted by 150 bps.
Earnings per share at €1.26, down from €1.62 in 2024.
Dividend proposed at €0.40, up from €0.38.
Free cash flow rose 48% to €152.4m, enabling debt and leverage reduction.
Outlook and guidance
Revenue expected to increase in the single-digit percentage range in 2026, driven by semi and defense markets.
EBITDA margin guidance for 2026 set at 19%-21%.
CapEx/investments projected slightly below 2025, trending toward maintenance levels.
Q1 2026 revenue expected below Q1 2025 due to order book structure and capacity.
Guidance assumes stable political and economic conditions.
Latest events from Jenoptik
- 2026 guidance targets single-digit revenue growth and higher margins after a challenging 2025.JEN
German Select VII Conference15 Apr 2026 - 2025 saw lower revenue but improved cash flow, with growth expected to resume in 2026.JEN
Investor presentation25 Mar 2026 - Revenue and earnings up, 2024 guidance confirmed amid robust semiconductor demand.JEN
Q2 20241 Feb 2026 - Revenue and EBITDA rose, but 2025 targets postponed to 2026 amid industry delays.JEN
Q3 202415 Jan 2026 - Revenue and profit fell in H1 2025, with guidance cut amid ongoing global uncertainties.JEN
Q2 20256 Jan 2026 - 2024 saw strong growth and margins, but 2025 outlook is cautious amid persistent uncertainties.JEN
Q4 20243 Dec 2025 - Revenue and EBITDA fell, but free cash flow and order intake improved amid market uncertainty.JEN
Q3 202512 Nov 2025 - Revenue and profit fell, but Biophotonics and cash flow improved; outlook remains cautious.JEN
Q1 20256 Jun 2025 - Record revenue and EBITDA in 2024, led by semiconductor growth, despite market headwinds.JEN
Q4 2024 TU5 Jun 2025